Robert W. Baird Reiterates Buy Rating for PRA Health Sciences, Inc. (PRAH)

Robert W. Baird reaffirmed their buy rating on shares of PRA Health Sciences, Inc. (NASDAQ:PRAH) in a research report released on Monday morning. Robert W. Baird currently has a $88.00 price target on the medical research company’s stock.

Other equities research analysts also recently issued research reports about the company. BidaskClub downgraded PRA Health Sciences from a strong-buy rating to a buy rating in a research report on Monday, July 31st. Citigroup Inc. reissued a buy rating and set a $90.00 price target (up previously from $73.00) on shares of PRA Health Sciences in a research report on Wednesday, June 28th. Bank of America Corporation started coverage on PRA Health Sciences in a research report on Monday, June 26th. They set a buy rating and a $89.00 price target on the stock. Zacks Investment Research raised PRA Health Sciences from a hold rating to a buy rating and set a $83.00 price target on the stock in a research report on Tuesday, August 15th. Finally, Jefferies Group LLC reissued a buy rating and set a $92.00 price target (up previously from $88.00) on shares of PRA Health Sciences in a research report on Thursday, August 10th. One analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The stock has an average rating of Buy and an average price target of $84.78.

Shares of PRA Health Sciences (NASDAQ:PRAH) opened at 81.55 on Monday. The firm has a 50 day moving average price of $76.93 and a 200-day moving average price of $72.64. PRA Health Sciences has a 12 month low of $50.87 and a 12 month high of $82.00. The company has a market cap of $5.11 billion, a P/E ratio of 52.65 and a beta of 0.42.

PRA Health Sciences (NASDAQ:PRAH) last posted its earnings results on Monday, August 7th. The medical research company reported $0.62 EPS for the quarter, missing the consensus estimate of $0.72 by ($0.10). PRA Health Sciences had a net margin of 5.15% and a return on equity of 21.17%. The firm had revenue of $457.90 million during the quarter, compared to analyst estimates of $447.79 million. During the same period in the previous year, the company posted $0.63 EPS. PRA Health Sciences’s revenue for the quarter was up .5% compared to the same quarter last year. Analysts anticipate that PRA Health Sciences will post $3.19 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by BBNS and is the sole property of of BBNS. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://baseballnewssource.com/markets/robert-w-baird-reiterates-buy-rating-for-pra-health-sciences-inc-prah/1704547.html.

In other PRA Health Sciences news, major shareholder Pra Investors L.P. Kkr sold 9,500,000 shares of the company’s stock in a transaction on Monday, August 14th. The stock was sold at an average price of $74.85, for a total transaction of $711,075,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Colin Shannon sold 400,000 shares of the company’s stock in a transaction on Monday, August 14th. The stock was sold at an average price of $74.85, for a total value of $29,940,000.00. The disclosure for this sale can be found here. Insiders have sold 10,000,000 shares of company stock valued at $748,500,000 over the last 90 days. Corporate insiders own 2.10% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Dynamic Technology Lab Private Ltd bought a new stake in PRA Health Sciences during the second quarter worth $359,000. Ameritas Investment Partners Inc. lifted its stake in shares of PRA Health Sciences by 62.9% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,404 shares of the medical research company’s stock valued at $255,000 after acquiring an additional 1,315 shares during the last quarter. California State Teachers Retirement System lifted its stake in shares of PRA Health Sciences by 44.1% in the 2nd quarter. California State Teachers Retirement System now owns 68,668 shares of the medical research company’s stock valued at $5,151,000 after acquiring an additional 21,031 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of PRA Health Sciences by 56.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 30,553 shares of the medical research company’s stock valued at $2,292,000 after acquiring an additional 11,057 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its stake in shares of PRA Health Sciences by 160.7% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 99,600 shares of the medical research company’s stock valued at $7,471,000 after acquiring an additional 61,400 shares during the last quarter. Hedge funds and other institutional investors own 98.37% of the company’s stock.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Analyst Recommendations for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston Astros Relying on Justin Verlander to Save Their Season
Houston Astros Relying on Justin Verlander to Save Their Season
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Aaron Judge and Gary Sanchez Have Break Out Games
Aaron Judge and Gary Sanchez Have Break Out Games
Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation


Leave a Reply

 
© 2006-2017 BBNS.